Logo image of VRNA

VERONA PHARMA PLC - ADR (VRNA) Stock Fundamental Analysis

NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD

91.08  +1 (+1.11%)

Fundamental Rating

3

VRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. VRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRNA has reported negative net income.
VRNA had a negative operating cash flow in the past year.
VRNA had negative earnings in each of the past 5 years.
VRNA had a negative operating cash flow in each of the past 5 years.
VRNA Yearly Net Income VS EBIT VS OCF VS FCFVRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of VRNA (-31.17%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -72.35%, VRNA is in line with its industry, outperforming 46.15% of the companies in the same industry.
Industry RankSector Rank
ROA -31.17%
ROE -72.35%
ROIC N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
VRNA Yearly ROA, ROE, ROICVRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

Looking at the Gross Margin, with a value of 33.49%, VRNA is in line with its industry, outperforming 57.95% of the companies in the same industry.
VRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRNA Yearly Profit, Operating, Gross MarginsVRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRNA has been increased compared to 1 year ago.
VRNA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VRNA is higher compared to a year ago.
VRNA Yearly Shares OutstandingVRNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRNA Yearly Total Debt VS Total AssetsVRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

VRNA has an Altman-Z score of 14.19. This indicates that VRNA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 14.19, VRNA belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
VRNA has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
VRNA's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. VRNA is outperformed by 71.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z 14.19
ROIC/WACCN/A
WACC9.24%
VRNA Yearly LT Debt VS Equity VS FCFVRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.86 indicates that VRNA has no problem at all paying its short term obligations.
VRNA has a better Current ratio (8.86) than 80.00% of its industry peers.
A Quick Ratio of 8.73 indicates that VRNA has no problem at all paying its short term obligations.
VRNA's Quick ratio of 8.73 is fine compared to the rest of the industry. VRNA outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 8.86
Quick Ratio 8.73
VRNA Yearly Current Assets VS Current LiabilitesVRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VRNA have decreased strongly by -163.16% in the last year.
VRNA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.86% yearly.
EPS 1Y (TTM)-163.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VRNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.15% on average per year.
The Revenue is expected to grow by 123.46% on average over the next years. This is a very strong growth
EPS Next Y102.36%
EPS Next 2Y64.09%
EPS Next 3Y50.65%
EPS Next 5Y19.15%
Revenue Next Year988.8%
Revenue Next 2Y341.4%
Revenue Next 3Y195.04%
Revenue Next 5Y123.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRNA Yearly Revenue VS EstimatesVRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VRNA Yearly EPS VS EstimatesVRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRNA. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 60.88 indicates a quite expensive valuation of VRNA.
VRNA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. VRNA is cheaper than 68.21% of the companies in the same industry.
VRNA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.76.
Industry RankSector Rank
PE N/A
Fwd PE 60.88
VRNA Price Earnings VS Forward Price EarningsVRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRNA Per share dataVRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

VRNA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VRNA's earnings are expected to grow with 50.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y64.09%
EPS Next 3Y50.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (7/3/2025, 11:06:06 AM)

91.08

+1 (+1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners74.02%
Inst Owner Change5.57%
Ins Owners10.87%
Ins Owner Change-4.08%
Market Cap7.74B
Analysts84.71
Price Target98.29 (7.92%)
Short Float %13%
Short Ratio6.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.32%
Min EPS beat(2)-34.07%
Max EPS beat(2)-4.58%
EPS beat(4)0
Avg EPS beat(4)-60.23%
Min EPS beat(4)-192.46%
Max EPS beat(4)-4.58%
EPS beat(8)3
Avg EPS beat(8)-23.74%
EPS beat(12)4
Avg EPS beat(12)-23.95%
EPS beat(16)8
Avg EPS beat(16)-6.04%
Revenue beat(2)2
Avg Revenue beat(2)24.41%
Min Revenue beat(2)8.73%
Max Revenue beat(2)40.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.43%
PT rev (3m)19.95%
EPS NQ rev (1m)-98.51%
EPS NQ rev (3m)104.77%
EPS NY rev (1m)-84.08%
EPS NY rev (3m)-81.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)35.34%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)34.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 60.88
P/S 65.33
P/FCF N/A
P/OCF N/A
P/B 34.17
P/tB 34.26
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)1.5
Fwd EY1.64%
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS1.39
BVpS2.67
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.17%
ROE -72.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.49%
FCFM N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.83%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.86
Quick Ratio 8.73
Altman-Z 14.19
F-Score2
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y102.36%
EPS Next 2Y64.09%
EPS Next 3Y50.65%
EPS Next 5Y19.15%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year988.8%
Revenue Next 2Y341.4%
Revenue Next 3Y195.04%
Revenue Next 5Y123.46%
EBIT growth 1Y-89.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.58%
EBIT Next 3Y91.37%
EBIT Next 5YN/A
FCF growth 1Y-137.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135%
OCF growth 3YN/A
OCF growth 5YN/A